Drug major Lupin today announced the acquisition of Netherlands-based Nanomi BV for an undisclosed amount.
With this, the company has made its foray into the technology-intensive injectables space, Lupin Ltd said in a statement.
"With the use of Nanomi's proprietary technology platform, Lupin would be able to make significant in-roads into the niche area of complex injectables," Lupin Chief Executive Officer Vinita Gupta said.
Nanomi has a rich talent pool of scientists who would be backed by Lupin's global R&D and manufacturing teams, the Mumbai-based firm said.
Lupin shares closed at Rs 921.90 on the BSE Sensex, up 4.52 per cent.